Compare EQT & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQT | IQV |
|---|---|---|
| Founded | 1925 | 1982 |
| Country | United States | United States |
| Employees | 1873 | 93000 |
| Industry | Oil & Gas Production | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6B | 34.6B |
| IPO Year | 1994 | 2013 |
| Metric | EQT | IQV |
|---|---|---|
| Price | $48.68 | $206.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 16 |
| Target Price | $69.15 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 6.2M | 1.5M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ 635.56 | 4.67 |
| EPS | ★ 2.36 | 1.61 |
| Revenue | $8,644,211,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $20.28 | $6.77 |
| Revenue Next Year | N/A | $5.89 |
| P/E Ratio | ★ $21.23 | $129.93 |
| Revenue Growth | ★ 63.92 | 41.60 |
| 52 Week Low | $48.47 | $154.50 |
| 52 Week High | $68.24 | $247.05 |
| Indicator | EQT | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 29.76 | 67.75 |
| Support Level | N/A | $206.72 |
| Resistance Level | $57.62 | $209.48 |
| Average True Range (ATR) | 1.23 | 6.63 |
| MACD | -0.09 | 1.95 |
| Stochastic Oscillator | 12.21 | 92.08 |
EQT is an independent natural gas production company. It focuses its operations in the cores of the Marcellus and Utica shales, located in the Appalachian Basin in the Eastern United States. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has three reportable segments in production, gathering, and its transmission segment, which is now an operated joint venture with Blackstone. All the firm's operating revenue is generated in the US, with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.